推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome.

KA Sauter, LJ Wood, J Wong… - Cancer biology & …, 2011 - ncbi.nlm.nih.gov
Anthracyclines including doxorubicin and daunorubicin are commonly used for the treatment
of both hematologic and solid tumors. Dose related adverse effects often limit the effectiveness
of anthracyclines in chemotherapy. Drug-related systemic inflammation mediated by ...
All 5 versions

Liposomal Encapsulation of a Synergistic Molar Ratio of Cytarabine and Daunorubicin Enhances Selective Toxicity for Acute Myeloid Leukemia Progenitors as …

HP Kim, B Gerhard, TO Harasym, LD Mayer… - Experimental …, 2011 - Elsevier
AML blasts and progenitors from patients who achieved complete remission were more sensitive
to both CPX-351 and free drugs than the same cells from patients with chemotherapy refractory
leukemia. However, AML CFC and CD34 + CD38 - AML blasts (enriched for candidate ...
All 2 versions

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid …

[HTML] from hematologylibrary.orgS Ohtake, S Miyawaki, H Fujita… - …, 2011 - bloodjournal.hematologylibrary.org
We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin
would be as effective as standard-dose idarubicin in remission-induction therapy for newly diagnosed
adult patients younger than 65 years of age with acute myeloid leukemia. Of 1064 ...
Cited by 13 - Related articles - All 4 versions

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B …

MR Baer, SL George, BL Sanford, K Mrózek… - Leukemia, 2011 - nature.com
Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients 60
years received intensified chemotherapy, including daunorubicin 60 mg/m 2 and etoposide 100
mg/m 2 during days 1, 2, 3 with cytarabine 100 mg/m 2 during days 1–7, with a second ...
Cited by 3 - Related articles - All 4 versions

AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.

L Zhong, H Shen, C Huang, H Jing… - Toxicology and applied …, 2011 - ncbi.nlm.nih.gov
Daunorubicin, idarubicin, doxorubicin and epirubicin are anthracyclines widely used for the treatment
of lymphoma, leukemia, and breast, lung, and liver cancers, but tumor resistance limits their clinical
success. Aldo-keto reductase family 1 B10 (AKR1B10) is an NADPH-dependent enzyme ...

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451